natgillin/translations-raw huggingface dataset:
Improvements in the mean PDSS-2 total score were 5.9 (rotigotine, baseline 19.3) and 1.9 points (placebo, baseline 20.5).
Poboljšanje u ukupnoj prosječnoj ocjeni prema PDSS-2 ljestvici bila je 5,9 bodova (rotigotin, početno 19,3), i 1,9 bodova (placebo, početno 20,5).
Improvements in the time patients lived without their disease getting worse when treated with Opdivo plus ipilimumab relative to Opdivo used on its own were only seen for patients whose cancer cells produced low levels of PD-L1.
Poboljšanja u vremenu tijekom kojeg su bolesnici živjeli bez pogoršanja bolesti kada su bili liječeni lijekom Opdivo u kombinaciji s ipilimumabom u usporedbi s lijekom Opdivo kao monoterapijom pokazalo se samo u bolesnika čije su stanice raka proizvodile niske koncentracije bjelančevine PD-L1.
Improvements observed in PFS were consistent across subsets regardless of age (< 65 versus ≥ 65), risk status, presence or absence of cytogenetic categories del17p or t(4;14), ISS stage, number of prior therapies, prior immunomodulatory exposure, prior bortezomib exposure, relapsed or refractory status or renal function as shown in Table 6.
Primijećena poboljšanja PFS-a bila su dosljedna u svim podskupinama, neovisno o dobi (< 65 naspram ≥ 65 godina), rizičnom statusu, prisutnosti ili odsutnosti citogenetskih kategorija del17p ili t(4;14), stadiju prema ISS klasifikaciji, broju prethodnih terapija, prethodnoj izloženosti imunomodulatorima, prethodnoj izloženosti bortezomibu, relapsnom ili refraktornom statusu ili funkciji bubrega, kao što je prikazano u Tablici 6.
Improvements or stabilisation were seen in Child- Pugh-Turcotte score.
Poboljšanja ili stabilizacija uočeni su u rezultatu na ljestvici Child-Pugh-Turcotte.
Improvements were also seen in the study of children taking the film-coated tablets.
Poboljšanja su također uočena u ispitivanjima provedenima u djece koja su uzimala filmom obložene tablete.
Improvements were observed for waist circumference (including subjects with type 2 diabetes), triglycerides, HDL-C and LDL-C/HDL-C ratio for subjects treated with naltrexone / bupropion vs. placebo in all Phase 3 studies (Table 4).
Opažena su poboljšanja obujma struka (uključujući ispitanike s dijabetesom tipa 2), triglicerida, HDL-K i LDL-K/HDL-K omjera za ispitanike liječene naltrekson / bupropionom naspram placeba u svim ispitivanjima faze 3 (Tablica 4).
Improvements were observed with cardiac index with all three sildenafil groups over placebo, 10 %, 4 % and 15 % for the low, medium and high dose groups respectively.
Poboljšanja srčanog indeksa opažena su u sve tri skupine liječene sildenafilom u odnosu na placebo: 10% u skupini koja je primala nisku dozu, 4% u skupini koja je primala srednju dozu i 15% u skupini koja je primala visoku dozu sildenafila.
Impulse control disorder (see below)
poremećaj kontrole impulsa (vidjeti u nastavku)
Impulse control disorders (ICDs)
Poremećaji kontrole impulsa
Impulse control disorders* (Libido increased, hypersexuality, pathological gambling, compulsive spending or buying, binge eating, compulsive eating (see section 4.4))
poremećaj kontrole impulsa⃰ (povećanje libida, hiperseksualnost, patološko kockanje, kompulzivno trošenje ili kupovanje, prejedanje kompulzivno jedenje (vidjeti dio 4.4))
Impulse control disorders* (Libido increased, hypersexuality, pathological gambling, compulsive spending or buying, binge eating, compulsive eating (see section 4.4))
poremećaj kontrole impulsa⃰ (povećanje libida, hiperseksualnost, patološko kockanje, kompulzivno trošenje ili kupovanje, prejedanje, kompulzivno jedenje (vidjeti dio 4.4))
Impulse control disorders: Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa including Corbilta (see section 4.4).
Poremećaji kontrole impulsa: Patološko kockanje, pojačani libido, hiperseksualnost, kompulzivno trošenje ili kupovanje, prejedanje i kompulzivno jedenje mogu se javiti u bolesnika liječenih agonistima dopamina i/ili drugim dopaminergičkim lijekovima koji sadrže levodopu, uključujući Corbiltu (vidjeti dio 4.4).
Impulse control disorders: Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa including Stalevo (see section 4.4).
Poremećaji kontrole impulsa: Patološko kockanje, pojačani libido, hiperseksualnost, kompulzivno trošenje ili kupovanje, prejedanje i kompulzivno jedenje mogu se javiti u bolesnika liječenih agonistima dopamina i/ili drugim dopaminergičkim lijekovima koji sadrže levodopu, uključujući Stalevo (vidjeti dio 4.4).
Impulse control disorders: Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments such as Entacapone Orion in association with levodopa (see section 4.4).
Poremećaji kontrole impulsa: Patološko kockanje, pojačan libido, hiperseksualnost, kompulzivno trošenje ili kupovanje, nekontrolirano prejedanje i kompulzivno jedenje mogu se javiti u bolesnika liječenih agonistima dopamina i/ili drugim dopaminergicima poput Entacapone Oriona zajedno s levodopom (vidjeti dio 4.4).
Impulse control disorders: Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments such as Entacapone Teva in association with levodopa (see section 4.4).
Poremećaji kontrole impulsa: patološko kockanje, pojačan libido, hiperseksualnost, kompulzivno trošenje ili kupovanje, nekontrolirano prejedanje i kompulzivno jedenje mogu se javiti u bolesnika liječenih agonistima dopamina i/ili drugim dopaminergicima poput Entakapona Teva zajedno s levodopom (vidjeti dio 4.4).
Imputations according to the TLOVR algorithm
Pripisane vrijednosti izračunate prema TLOVR algoritmu.
Imrestor 15 mg solution for injection for cattle
Imrestor 15 mg otopina za injekciju za goveda
Imrestor 15 mg solution for injection for cattle pegbovigrastim
Imrestor 15 mg otopina za injekciju za goveda pegbovigrastim
imultaneous administration)
na dan, primjena u isto vrijeme)
Imvanex contains a modified form of the vaccinia virus called vaccinia Ankara, which does not cause disease in humans and cannot replicate (reproduce) in human cells.
Imvanex sadrži modificirani oblik virusa vakcinije zvan „vakcinacija Ankara” koji ne uzrokuje bolest u ljudi i ne može se razmnožavati u ljudskim stanicama.
IMVANEX contains Sodium
IMVANEX sadrži natrij
Imvanex has been authorised under ‘exceptional circumstances’.
Imvanex je odobren pod „iznimnim okolnostima”.
Imvanex is a vaccine used to protect against smallpox in adults.
Imvanex je cjepivo za zaštitu od velikih boginja u odraslih.
Imvanex is available as a suspension for injection under the skin, preferably in the upper arm.
Imvanex je dostupan kao suspenzija za injekciju pod kožu, po mogućnosti u nadlakticu.
Imvanex live modified vaccinia Ankara virus
Imvanex živi modificirani virus vakcinije Ankara
Imvanex must not be used in patients who are hypersensitive (allergic) to the active substance or any of the substances found at trace levels, such as chicken protein, benzonase and gentamicin.
Imvanex se ne smije koristiti u bolesnika koji su preosjetljivi (alergični) na djelatnu tvar ili bilo koju tvar u tragovima poput pilećih proteina, benzonaza i gentamicina.
IMVANEX suspension for injection
IMVANEX suspenzija za injekciju
Imvanex would therefore be beneficial for people who cannot be given vaccines containing replicating viruses, such as patients with a weakened immune system.
Imvanex bi stoga bio koristan za osobe koje ne mogu primiti cjepiva koja sadrže replicirajuće viruse, kao što su bolesnici s oslabljenim imunološkim sustavom.
IMVANEX® suspension for injection Smallpox vaccine
IMVANEX® suspenzija za injekciju Cjepivo protiv velikih boginja
imvastatin (a medicine used to control high cholesterol levels);
imvastatin (lijekovi koji se koriste za kontrolu visokih razina kolesterola);
imvastatin (a medicine used to control high cholesterol levels);
imvastatinom (lijekovi koji se koriste za kontrolu visokih razina kolesterola);
imvastatin (a medicine used to lower cholesterol levels) since your dose may have to be adjusted;
njihovu učinkovitost. simvastatin (lijek za smanjenje razine kolesterola) jer će možda biti potrebno prilagoditi Vašu dozu.
imvastatin (used to lower cholesterol),
imvastatin (koristi se za sniženje kolesterola),
imvastatin and lovastatin (used to lower blood cholesterol).
imvastatin i lovastatin (primjenjuju se za snižavanje razine kolesterola u krvi).
imvastatin and lovastatin - for lowering blood cholesterol quetiapine – used to treat schizophrenia, bipolar disorder and major depressive disorder.
imvastatin i lovastatin – koriste se za snižavanje kolesterola u krvi kvetiapin – koristi se za liječenje shizofrenije, bipolarnog poremećaja i velikog depresivnog poremećaja
imvastatin and lovastatin – for lowering blood cholesterol quetiapine – used to treat schizophrenia, bipolar disorder and major depressive disorder.
imvastatin i lovastatin – koriste se za snižavanje kolesterola u krvi kvetiapin – koristi se za liječenje shizofrenije, bipolarnog poremećaja i velikog depresivnog poremećaja
imvastatin and possibly other statins (used to treat high cholesterol levels). medicines that reduce stomach acid.
imvastatin i moguće drugi statini (koriste se za liječenje visoke razine kolesterola). lijekove koji smanjuju kiselinu u želucu.
imvastatin or lovastatin (used to lower blood cholesterol)
imvastatin ili lovastatin (primjenjuju se za snižavanje kolesterola u krvi)
imvastatin, lovastatin (increased risk of myopathy including rhabdomyolysis)
imvastatin, lovastatin (povećan rizik od miopatije, uključujući rabdomiolizu)
imvastatin, lovastatin (used to lower blood cholesterol);
imvastatin, lovastatin (koriste se za snižavanje razina kolesterola u krvi);
imvastatin, lovastatin (used to lower cholesterol);
imvastatin, lovastatin (koji se koriste za smanjenje razine kolesterola);
In 1% of patients receiving dabrafenib as monotherapy in the integrated safety population in clinical trials, serious non-infectious febrile events were identified as fever accompanied by severe rigors, dehydration, hypotension and/or acute renal insufficiency or pre-renal origin in subjects with normal baseline renal function.
U 1% bolesnika koji su primali dabrafenib kao monoterapiju u integriranoj populaciji u kojoj se ispitivala sigurnost u kliničkim ispitivanjima, identificirani su događaji ozbiljne neinfektivne vrućice koji su bili definirani kao vrućica praćena jakom tresavicom, dehidracijom, hipotenzijom i/ili akutnom bubrežnom insuficijencijom prerenalnog podrijetla u bolesnika čije su početne vrijednosti bubrežne funkcije bile normalne.
In 1,094 patients with advanced phase CML or Ph+ ALL, the median duration of treatment for patients was 6.2 months (range 0-9.32 months).
U 1094 bolesnika u uznapredovaloj fazi KML ili Ph+ ALL, medijan trajanja liječenja u bolesnika bio je 6,2 mjeseca (raspon 0-9,32 mjeseca).
In 1-month rat and monkey toxicology studies, a mild decrease in red blood cell count, haematocrit and haemoglobin was observed.
U jednomjesečnim toksikološkim ispitivanjima na štakorima i majmunima uočeno je blago smanjenje broja crvenih krvnih stanica te vrijednosti hematokrita i hemoglobina.
In 1.1% of patients, hypertension led to permanent treatment discontinuation.
U 1,1% bolesnika, hipertenzija je dovela do trajnog prestanka liječenja.
In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 0.75 mg of ethinyl estradiol were studied.
U 10 zdravih žena proučavani su farmakokinetički profili noretindrona i etinil estradiola nakon primjene pojedinačne doze koja sadrži 1,0 mg noretindron acetata i 0,75 mg etinil estradiola.
In 10 therapeutic studies, the median for the average and maximum plasma concentrations in individual subjects across the studies was 2425 ng/ml (inter-quartile range 1193 to 4380 ng/ml) and 3742 ng/ml (inter- quartile range 2027 to 6302 ng/ml), respectively.
U 10 ispitivanja s terapijskom primjenom lijeka medijan prosječnih plazmatskih koncentracija u pojedinačnih ispitanika u svim ispitivanjima bio je 2425 ng/ml (interkvartilni raspon od 1193 do 4380 ng/ml), dok je medijan maksimalnih plazmatskih koncentracija iznosio 3742 ng/ml (interkvartilni raspon od 2027 do 6302 ng/ml).
In 100% human serum, the mean protein fold shift was 75 fold, resulting in protein adjusted IC90 of 0.064 ug/mL.
U 100%-tnom ljudskom serumu srednja vrijednost promjene ekspresije proteina iznosila je 75 puta, što je za posljedicu imalo vrijednost IC90 prilagođenu za proteine od 0,064 μg/ml.
In 109 patients with CTCL treated at the recommended initial dose of 300 mg/m2/day, the most commonly reported adverse reactions to Targretin were hyperlipaemia ((primarily elevated triglycerides) 74%), hypothyroidism (29%), hypercholesterolaemia (28%), headache (27%), leucopenia (20%), pruritus (20%), asthenia (19%), rash (16%), exfoliative dermatitis (15%), and pain (12%).
U 109 bolesnika s CTCL-om liječenih preporučenom početnom dozom od 300 mg/m2 na dan, najčešće zabilježene nuspojave Targretina bile su hiperlipemija ((primarno povišeni trigliceridi) 74%), hipotiroidizam (29%), hiperkolesterolemija (28%), glavobolja (27%), leukopenija (20%), pruritus (20%), astenija (19%), osip (16%), eksfolijativni dermatitis (15%) i bol (12%).
In 11 clinical trials in different indications 247 patients were treated with Zavesca at dosages of 50- 200 mg t.i.d. for an average duration of 2.1 years.
U 11 kliničkih ispitivanja s različitim indikacijama 247 bolesnika je liječeno Zavescom u dozama od 50- 200 mg triput dnevno, u prosječnom trajanju od 2,1 godine.
In 11 Pixuvri-treated patients, these events were grade 1-2 and in 2 patients they were grade 3; these events were transient and not Pixuvri dose related.
U 11 bolesnika liječenih Pixuvriom ova je pojava bila stupnja 1-2, a u 2 bolesnika stupnja 3.
In 114 cases there were no associated systemic events and these cases appear to represent a localised over-whitening effect.
U 114 slučajeva nije bilo povezanih sistemskih događaja i za ove slučajeve se čini da predstavljaju lokalizirani učinak prekomjernog blijeđenja.
In 119 imiquimod-treated female patients, the combined total clearance rate was 60% as compared to 20% in 105 vehicle-treated patients (95% CI for rate difference: 20% to 61%, p<0.001).
Kod 119 žena liječenih imikvimodom stopa potpunog nestanka bradavica bila je 60% u usporedbi s 20% u 105 bolesnica liječenih podlogom (95%-tni interval pouzdanosti, za omjer: 20% do 61% p < 0,001).
In 12 dogs suffering from atopic dermatitis, after topical application on the skin at the recommended therapeutic dosage for 28 to 70 consecutive days, no noticeable effect on the systemic cortisol level was observed.
U 12 pasa oboljelih od atopijskog dermatitisa nakon lokalne primijene na kožu preporučene doze tijekom 28-70 uzastopnih dana nije bilo vidljivog učinka na sustavni nivo kortizola.
In 12 patients who required major surgery during the study, control of blood loss was also rated as good or excellent by the patients’ doctors.
U 12 bolesnika kod kojih je bio potreban veći kirurški zahvat tijekom ispitivanja, liječnici bolesnika također su kontrolu gubitka krvi ocijenili dobrom ili izvrsnom.
In 12 patients with available data the AUC and Cmax were approximately equivalent to those observed for the 20 mg/kg dose group in the pivotal trial.
U 12 bolesnika za koje su podaci bili dostupni vrijednosti AUC i Cmax bile su otprilike jednake onima uočenima u skupini koja je u pivotalnom ispitivanju primala dozu od 20 mg/kg.
In 157 imiquimod-treated male patients, the combined total clearance rate was 23% as compared to 5% in 161 vehicle-treated patients (95%CI for rate difference: 3% to 36%, p<0.001).
Kod 157 liječenih muškaraca stopa potpunog nestanka bradavica bila je 23 % u usporedbi s 5% u 161 bolesnika liječenog podlogom (95%-tni CI za omjer: 3% do 36% p <0,001).
In 1722 patients treated with crizotinib with either ALK-positive or ROS1-positive NSCLC across clinical studies, the most frequent adverse reactions (≥3%) associated with dosing interruptions were neutropenia, elevated transaminases, vomiting, and nausea.
U 1722 bolesnika liječenih krizotinibom s ALK-ili ROS1- pozitivnim NSCLC-om u kliničkim ispitivanjima, najčešće nuspojave (≥3%) povezane s prekidom terapije su bile neutropenija, povišene transaminaze, povraćanje i mučnina.
In 190 subjects evaluable for objective tumour response, 55 subjects had GCTB surgery, out of which 40 subjects had complete resections.
U 190 ispitanika u kojih se mogao procijeniti objektivni odgovor tumora, 55 ispitanika je imalo operaciju gigantocelularnog tumora kosti, od kojih je 40 ispitanika imalo potpunu resekciju.
In 2 clinical trials, 1035 subjects were administered a second dose of ProQuad approximately 3 months after the first dose.
U 2 klinička ispitivanja, 1035 ispitanika primilo je drugu dozu cjepiva ProQuad približno 3 mjeseca nakon prve doze.
In 2 controlled clinical studies 955 thrombocytopenic patients with HCV infection were treated with eltrombopag.
U 2 kontrolirana klinička ispitivanja 955 bolesnika s trombocitopenijom i HCV infekcijom bilo je liječeno eltrombopagom.
In 2 controlled clinical studies in patients with HCV, ALT or AST  3 x ULN was reported in 34% and 38% of the eltrombopag and placebo groups, respectively.
U 2 kontrolirana klinička ispitivanja na bolesnicima s HCV-om, u 34% ispitanika koji su primali eltrombopag i 38% ispitanika koji su primali placebo zabilježene su razine ALT ili AST ≥ 3x iznad gornje granice normale.
In 2 controlled clinical studies in thrombocytopenic patients with HCV, hepatic decompensation (ascites, hepatic encephalopathy, variceal haemorrhage, spontaneous bacterial peritonitis) was reported more frequently in the eltrombopag arm (11%) than in the placebo arm (6%).
U 2 kontrolirana klinička ispitivanja trombocitopeničnih bolesnika s HCV-om, dekompenzacija jetre (ascites, hepatička encefalopatija, krvarenje iz varikoziteta, spontani bakterijski peritonitis) prijavljena je češće u skupini koja je primala eltrombopag (11%) nego u skupini koja je primala placebo (6%).
In 2 controlled clinical studies, 171 chronic paediatric ITP patients were treated with eltrombopag.
U 2 kontrolirana klinička ispitivanja, 171 pedijatrijski bolesnik s kroničnim ITP-om bio je liječen eltrombopagom.
In 2 large randomized, parallel group, double-blind, dose-confirmatory trials, patients undergoing elective major orthopaedic surgery (one for knee replacement surgery and one for hip replacement surgery) received Pradaxa 75 mg or 110 mg within 1-4 hours of surgery followed by 150 mg or 220 mg daily thereafter, haemostasis having been secured, or enoxaparin 40 mg on the day prior to surgery and daily thereafter.
U 2 velika, randomizirana, dvostruko slijepa ispitivanja, za potvrđivanje doze, u bolesnika podvrgnutih velikom elektivnom ortopedskom zahvatu (jedno za ugradnju endoproteze koljena i jedno za ugradnju endoproteze kuka), bolesnici su primili Pradaxu u dozi od 75 mg ili 110 mg unutar 1-4 sata nakon zahvata, nakon čega je slijedila svakodnevna primjena u dozi od 150 mg ili 220 mg, uz osiguranu hemostazu, ili enoksaparin u dozi od 40 mg na dan prije kirurškog zahvata i nakon toga svakodnevno.
In 2 of 14 subjects who had acute HIV infection at study enrollment, the K65R mutation was detected in the HIV of 1 of 5 subjects in the tenofovir disoproxil 245 mg (as fumarate) group and the M184V mutation (associated with resistance to emtricitabine) was detected in the HIV of 1 of 3 subjects in the Truvada group.
U 2 od 14 ispitanika koji su imali akutnu HIV-infekciju pri uključenju u ispitivanje, mutacija K65R bila je otkrivena u HIV-u kod 1 od 5 ispitanika u skupini koja je primala tenofovirdizoproksil u dozi od 245 mg (u obliku tenofovirdizoproksilfumarata), a mutacija M184V (povezana s rezistencijom na emtricitabin) bila je otkrivena u HIV-u kod 1 od 3 ispitanika u skupini koja je primala Truvadu.
In 2 other studies with patients seeking medical attention due to acute asthma symptoms, budesonide/formoterol provided rapid and effective relief of bronchoconstriction similar to salbutamol and formoterol.
U druga 2 ispitivanja s bolesnicima koji su zatražili medicinsku pomoć zbog akutne simptoma astme, budezonid/formoterol omogućio je brzo i učinkovito ublažavanje bronhokonstrikcije slično salbutamolu i formoterolu.
In 2 out of 30 dogs in the clinical trial infertility was not achieved until approximately 12 weeks after initial treatment, but in most cases these animals are not capable of successfully siring offspring.
U dva od 30 pasa, tijekom kliničkih pokusa, neplodnost nije postignuta približno 12 tjedana od početnoga tretmana, no u većini slučajeva životinje nisu bile sposobne za uspješno stvaranje potomstva.
In 2 Phase 1 studies, it was concluded that the potential for iron overload is minimal and no dose-dependent effects were observed in healthy volunteers.
U 2 ispitivanja faze 1 zaključeno je da je potencijal za preopterećenje željezom minimalan te da u zdravih dobrovoljaca nisu uočeni učinci ovisni o dozi.
In 2 phase III clinical trials decreased LVEF has been reported in 6 to 8% of patients treated with trametinib in combination with dabrafenib.with most cases being asymptomatic and reversible.
U dva klinička ispitivanja faze III smanjeni LVEF zabilježen je u 6 do 8% bolesnika liječenih trametinibom u kombinaciji s dabrafenibom, pri čemu je većina slučajeva bila asimptomatska i reverzibilna.
In 2 pivotal, double-blind, placebo-controlled, clinical trials, a total of 424 patients with euvolaemic or hypervolaemic hyponatraemia (serum sodium <135 mEq/l) due to a variety of underlying causes (heart failure [HF], liver cirrhosis, SIADH and others) were treated for 30 days with tolvaptan (n=216) or placebo (n=208) at an initial dose of 15 mg/day.
U 2 pivotalna, dvostruko slijepa klinička ispitivanja kontrolirana placebom, ukupan broj od 424 bolesnika s euvolemičnom ili hipervolemijskom hiponatremijom (serumski natrij <135 mEq/l) iz raznih razloga (zatajenje srca , ciroza jetre, SIADH i drugi) liječen je 30 dana sa tolvaptanom (n= 216) ili placebom (n=208) s početnom dozom od 15 mg/dan.
In 2 pivotal, double-blind, placebo-controlled, clinical trials, a total of 424 patients with euvolaemic or hypervolaemic hyponatraemia (serum sodium <135 mEq/l) due to a variety of underlying causes (heart failure [HF], liver cirrhosis, SIADH and others) were treated for 30 days with tolvaptan (n=216) or placebo (n=208) at an initial dose of 15 mg/day.
U 2 pivotalna, dvostruko slijepa klinička ispitivanja kontrolirana placebom, ukupan broj od 424 bolesnika s euvolemičnom ili hipervolemijskom hiponatremijom (serumski natrij <135 mEq/l) iz raznih razloga (zatajenje srca, ciroza jetre, SIADH i drugi) liječen je 30 dana sa tolvaptanom (n= 216) ili placebom (n=208) s početnom dozom od 15 mg/dan.
In 2 randomised, double-blind studies encompassing a total of 1,094 adult patients receiving chemotherapy that included cisplatin  70 mg/m2, aprepitant in combination with an ondansetron/dexamethasone regimen (see section 4.2) was compared with a standard regimen (placebo plus ondansetron 32 mg intravenously administered on Day 1 plus dexamethasone 20 mg orally on Day 1 and 8 mg orally twice daily on Days 2 to 4).
U dva randomizirana, dvostruko slijepa ispitivanja s ukupno 1094 odraslih bolesnika koji primaju kemoterapiju koja je uključivala cisplatin u dozi od ≥70 mg/m2, uspoređen je režim liječenja aprepitantom u kombinaciji s ondanzetronom/deksametazonom (vidjeti dio 4.2) sa standardnim režimom (placebo s ondanzetronom primijenjenim intravenski u dozi od 32 mg 1. dan te peroralnim deksametazonom u dozi od 20 mg 1. dan i 8 mg dvaput na dan 2. do 4. dana).